Small Molecules Targeting Defective RNAs Show Therapeutic Potential in Prostate Cancer

Small Molecules Targeting Defective RNAs Show Therapeutic Potential in Prostate Cancer
Scientists at Florida's Scripps Research Institute have developed a new drug candidate targeting prostate cancer, highlighting the therapeutic potential of a new class of drugs called small molecule RNA inhibitors. The study, "Defining RNA–Small Molecule Affinity Landscapes Enables Design of a Small Molecule Inhibitor of an Oncogenic Noncoding RNA,” appeared in the journal ACS Central Science. "This is like designing a scalpel to precisely seek out and destroy a cancer — but with a pill and without surgery," Scripps professor Matthew Disney, the study's lead author, said in a
Subscribe or to access all post and page content.